InvestorsHub Logo
Followers 198
Posts 9869
Boards Moderated 0
Alias Born 06/14/2006

Re: Biotech_Tradez post# 25530

Thursday, 02/22/2018 1:55:12 PM

Thursday, February 22, 2018 1:55:12 PM

Post# of 33238
Yeah. Kinda like the last warrants on their last 10Q right? And it was 15 million not 5 million. Geez man what could I possibly do or say at this point to make the stock go down. Games? It's doing it all by itself. SMH.

LOS ANGELES, CA--(Marketwired - Nov 28, 2016) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of non-invasive electroceuticals for the treatment of inflammatory conditions and diseases in vital organs, today announced that it has signed a term sheet with a single strategic healthcare investor for $5 million in Series B Preferred Stock financing to redeem all of its outstanding convertible notes, fund several pre-clinical studies targeting vascular diseases and ischemic injuries in vital organs and to prepare to uplist the Company's common stock onto a national stock exchange.

The financing, subject to the signing of a definitive agreement, will be used to buy back approximately $2.2 million in Company convertible notes in order to preserve shareholder value, prevent additional dilution from the conversion of notes payable and to strengthen the Company's balance sheet. The strategic healthcare investor is serving as lead investor in a larger $15 million proposed financing to uplist the Company's common stock onto a national stock exchange in the first half of 2017.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENDV News